Safety and efficacy of sacubitril/valsartan vs. benazepril administered as initial treatment for STEMI patients with mid-range ejection fraction: a propensity score matching analysis - Takeaways - MDSpire

Safety and efficacy of sacubitril/valsartan vs. benazepril administered as initial treatment for STEMI patients with mid-range ejection fraction: a propensity score matching analysis

  • By

  • Yanbo Wang

  • Lifang Su

  • Qing Zhou

  • Jia Tian

  • Wei Zhi

  • Yang Fu

  • Qing Wang

  • Yunfa Jiang

  • Xinshun Gu

  • May 28, 2026

  • 0 min

Share

  • 1

    This study compared the safety and efficacy of sacubitril/valsartan and benazepril in STEMI patients with mid-range LVEF (40%-49%).

  • 2

    After propensity score matching, 35 patients were included in each treatment group, ensuring balanced baseline characteristics.

  • 3

    The sacubitril/valsartan group showed significantly greater improvements in left ventricular function compared to the benazepril group after one month.

  • 4

    There were no significant differences in major adverse cardiac events or safety outcomes between the two treatment groups.

  • 5

    The findings suggest that sacubitril/valsartan may be more effective for short-term cardiac function improvement in this patient population.

Original Source(s)

Safety and efficacy of sacubitril/valsartan vs. benazepril administered as initial treatment for STEMI patients with mid-range ejection fraction: a propensity score matching analysis

  • by Yanbo Wang, Lifang Su, Qing Zhou, Jia Tian, Wei Zhi, Yang Fu, Qing Wang, Yunfa Jiang, Xinshun Gu

  • May 28, 2026

Related Content

Heterogeneous benefit of early sacubitril/valsartan initiation after PCI in elderly patients with left ventricular dysfunction: myocardial recovery and mid-term cardiovascular outcomes

Identification and validation of STEAP3 as a ferroptosis-related biomarker in heart failure

How Quickly Are Patients Reaching Quadruple HFrEF Therapy?

Delays in initiating guideline-directed quadruple therapy may increase early clinical risk in heart failure with reduced ejection fraction.